Accelerating Medicines Partnership - Alzheimer's

Research Areas

- Tool Development Resource
- Biomarker Research Diagnostic, Genomic Biomarker
- Basic Research
- Data-Sharing Enabler

At a Glance

- Status: Active Consortium
- Year Launched: 2014
- Initiating Organization: Foundation for the National Institutes of Health
- Initiator Type: Nonprofit foundation
- Location: North America

Abstract

The Accelerating Medicines Partnership (AMP) is a consortium of the National Institutes of Health (NIH), 10 biopharmaceutical companies, and several nonprofit organizations. The AMP Alzheimer’s Disease (AMP-AD) program focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets over the course of five years.

Mission

AMP brings together government, industry, and nonprofit organizations to identify and validate the most promising biological targets of disease for new diagnostic and drug development. The AMP AD project seeks to identify biomarkers that can predict clinical outcomes, and to conduct a large-scale analysis of human AD patient brain tissue samples with network modeling approaches and experimental validation, to increase the understanding of molecular pathways involved in AD, and to identify new potential therapeutic targets. The partnership consists of two projects: 1) a Biomarkers
Project, that explores the utility of tau imaging and novel fluid biomarkers for tracking responsiveness to treatment and/or disease progression, and 2) a Target Discovery and Preclinical Validation Project, that seeks to shorten the time between discovery of potential drug targets to development of new drugs for Alzheimer’s treatment and prevention. Each project has several investigators from different institutions that are utilizing complementary strategies to achieve the goals of the project.

Consortium History

The AMP AD project began in early 2014 and will be a five-year endeavor.

Structure & Governance

The AMP-AD partnership is managed by the Foundation for the NIH (FNIH). NIH and industry partners share expertise and resources in an integrated governance structure that enables the best-informed scientific contributions from all participants. The AMP AD project is managed by a Steering Committee consisting of representatives from NIH, Foundation for the NIH (FNIH), the Food and Drug Administration (FDA), and participating companies and patient advocacy organizations. Investigators carrying out research on AMP grants are added to the Steering Committee. The Steering Committee operates under the overall AMP Executive Committee, which includes representatives from NIH, industry partners, FDA, and patient advocacy organizations. The AMP-AD Steering Committee convenes monthly to discuss project plans and review ongoing progress and milestones. The Steering Committee is responsible for reporting project plans and milestones to the Executive Committee for review and approval. NIA program staff members provide scientific and administrative direction and oversee the cooperative grants that constitute the Target Discovery and the Biomarkers AMP-AD consortia. The AMP-AD program has several working groups that bring together scientists from the academic and industry teams. Face-to-face meetings organized by NIA with support from the FNIH provide an additional venue for communication and coordination.

Financing

AMP-AD budget: 5 years
Intellectual Property

AMP is designed to be precompetitive and will neither make use of preexisting intellectual property nor produce patentable findings.

Patent Engagement

The AMP AD project is supported by several nonprofit groups working on behalf of people with AD. These include the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation, FNIH, the Geoffrey Beene Foundation, and USAgainstAlzheimer’s.

Data Sharing

To achieve the central goals of AMP-AD, grant awardees are expected to engage in broad sharing of biological data, analytical methodology, and disease models before publication. Rapid sharing of data and analytical tools in AMP-AD is enabled through the AMP-AD Knowledge Portal.

Impact/Accomplishment

This five-year endeavor, beginning in 2014, will result in several sets of project outcomes. Each academic team is generating high dimensional data from a postmortem brain sample cohort as well as from an animal or cellular model system over the course of a 5 year grant. These projects are structured such that human data will be generated and released in the first years of the grant with the model system data and analytical results to follow. Data is deposited by each partner on a quarterly basis, with data from one quarter set to go public in the release scheduled for the following quarter. Data are updated and versioned in this portal as they are developed with older versions of data remaining available through the portal. Data may be used by the research community immediately and are not under embargo of any kind.
Links/Social Media Feed

Homepage

https://www.nia.nih.gov/alzheimers/amp-ad

Sponsors & Partners

Government

National Institute on Aging
National Institute of Neurological Disorders and Stroke
Food and Drug Administration (FDA)

Industry

AbbVie
Biogen
Eli Lilly
GSK

Nonprofit

Foundation for the NIH (FNIH)
Alzheimer’s Association
Alzheimer’s Drug Discovery Foundation
Geoffrey Beene Foundation
USAAgainstAlzheimer’s

Updated: 06/20/2017